This is an oral presentation, not a poster, which gives it extra prominence. Also notice date--coming right up--
Asterias today announced that clinical data from its AST-VAC1 (antigen-presenting autologous dendritic cells) immunotherapy clinical program will be presented during an oral session at the upcoming American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting, to be held on May 4-7, 2016 in Washington, D.C.
"...the lift on the partial hold will affect several drugs in the pipeline along with their extensive library of MPAC's...."
Exactly what I was thinking, kad.
Illumina has been right over the last decade--certainly righter than these message board posters who suddenly appear out of the woodwork. I'm thinking they feel good about their future.
The short term of these warrants does seem to be a signal that the company feels hope for the OPC1 dose escalation trial.
Remember, it's now a clinically meaningful dose--it's in cervical, not thoracic injuries (more likely to see improvements)--and, the results will be visible so we will not necessarily have to wait for data. (Oh, AND THEY'RE FREE!)